Achilles Tendinopathy Market

Market Overview:

The 7 major Achilles tendinopathy markets reached a value of USD 1,245.7 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,879.5 Million by 2035, exhibiting a growth rate (CAGR) of 3.81% during 2025-2035.

The Achilles tendinopathy market has been comprehensively analyzed in IMARC's new report titled "Achilles Tendinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Achilles tendinopathy is an overuse injury of the Achilles tendon, the band of tissue that joins the calf muscles in the rear of the lower leg to the heel bone. It tends to occur in runners who have unexpectedly increased the intensity or duration of their runs. The disease is typical among middle-aged adults who exclusively participate in weekend activities like tennis or basketball. Achilles tendinopathy pain usually starts as a minor aching in the back of the leg or above the heel after running or participating in another sport. Pain can become more acute after prolonged running, stair climbing, or sprinting. Patients may also have soreness or stiffness, particularly in the morning, which normally improves with little activity. Diagnosing Achilles tendinopathy commonly involves a comprehensive evaluation of characteristic features, medical history, and physical examination. The healthcare provider may also perform imaging tests, such as ultrasound that uses sound waves to visualize the Achilles tendon and provide real-time images of the tendon in motion.

The escalating prevalence of foot injuries that can lead to calf muscle atrophy or stiffness, reducing their ability to absorb stress and increasing Achilles tendon strain, is primarily driving the Achilles tendinopathy market. In addition to this, the inflating utilization of nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen and naproxen, to help alleviate pain and swelling in patients, is also creating a positive outlook for the market. Moreover, the widespread adoption of platelet-rich plasma injections, which are administered directly into the affected tendon to stimulate healing and reduce pain, is further bolstering the market growth. Apart from this, the rising usage of shockwave therapy on account of its several advantages, such as boosted tissue regeneration, increased collagen synthesis, and enhanced efficacy, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of glyceryl trinitrate patches, since they are designed to release glyceryl trinitrate, a medication that converts into nitric oxide in the body, to promote blood flow is expected to drive the Achilles tendinopathy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Achilles tendinopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Achilles tendinopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Achilles tendinopathy market in any manner.

Drugs:

NGI226, developed by Novartis is a monoclonal antibody therapy designed to treat Achilles tendinopathy by targeting nerve growth factor. The drug targets proteins known as Janus kinases, which when activated may play a role in tendinopathy. NGI226 can improve tendon structure and function, alleviating tendinopathy symptoms, by inhibiting the activation of these Janus kinases. It is administered as an injection to the leg near the Achilles tendon.

dHACM (dehydrated human amnion/chorion membrane) is a placental-based regenerative tissue therapy for Achilles tendinopathy. It contains growth factors, cytokines, and extracellular matrix proteins that stimulate tissue repair, reduce inflammation, and speed up tendon recovery. By regulating the immune response and increasing collagen synthesis, dHACM promotes cellular regeneration and decreases fibrosis, thereby restoring tendon structure and function while relieving pain.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Achilles tendinopathy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Achilles tendinopathy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Achilles tendinopathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Achilles tendinopathy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Achilles tendinopathy market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Achilles tendinopathy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of Achilles tendinopathy across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Achilles tendinopathy by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Achilles tendinopathy by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with Achilles tendinopathy across the seven major markets?
• What is the size of the Achilles tendinopathy patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of Achilles tendinopathy?
• What will be the growth rate of patients across the seven major markets?

Achilles Tendinopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Achilles tendinopathy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Achilles tendinopathy market?
• What are the key regulatory events related to the Achilles tendinopathy market?
• What is the structure of clinical trial landscape by status related to the Achilles tendinopathy market?
• What is the structure of clinical trial landscape by phase related to the Achilles tendinopathy market?
• What is the structure of clinical trial landscape by route of administration related to the Achilles tendinopathy market?